Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Intestinal2466 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A23717 | 23542537 | Biochem Pharmacol | The liver X receptor: a master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease. | 2013 | Details |
| A23719 | 23538296 | JPEN J Parenter Enteral Nutr | Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota? | 2013 | Details |
| A23783 | 23483818 | World J Gastroenterol | From fatty liver to fibrosis: a tale of "second hit". | 2013 | Details |
| A23810 | 23454028 | Clin Gastroenterol Hepatol | Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. | 2013 | Details |
| A23811 | 23453736 | Syst Appl Microbiol | Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula. | 2013 | Details |
| A23814 | 23452186 | Clin Microbiol Infect | Obesity, non-alcoholic fatty liver disease, and atherothrombosis: a role for the intestinal microbiota? | 2013 | Details |
| A23815 | 23452163 | Clin Microbiol Infect | Gut microbiota and non-alcoholic fatty liver disease: new insights. | 2013 | Details |
| A23843 | 23432669 | Curr Pharm Des | Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. | 2013 | Details |
| A23885 | 23403440 | J Pediatr Gastroenterol Nutr | Cholesteryl ester storage disease: protean presentations of lysosomal acid lipase deficiency. | 2013 | Details |
| A23886 | 23402636 | J Med Food | Health benefits of blue-green algae: prevention of cardiovascular disease and nonalcoholic fatty liver disease. | 2013 | Details |
| A23889 | 23401313 | Hepatology | Intestinal microbiota in patients with nonalcoholic fatty liver disease. | 2013 | Details |
| A23895 | 23360884 | Br J Nutr | Gut microbiota and metabolic disorders: How prebiotic can work? | 2013 | Details |
| A23906 | 23394094 | Curr Pharm Des | Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients? | 2013 | Details |
| A23908 | 23394092 | Curr Pharm Des | Pathophysiology of NASH: perspectives for a targeted treatment. | 2013 | Details |
| A23947 | 27785221 | Gastroenterology Res | Association Between Appendectomy and Fibrosis Progression in Nonalcoholic Fatty Liver Disease. | 2013 | Details |
| A23975 | 23332087 | Hepatol Res | Liver and diabetes. A vicious circle. | 2013 | Details |
| A23997 | 23317398 | Curr Pharm Des | Ezetimibe therapy for dyslipidemia: an update. | 2013 | Details |
| A23998 | 23316084 | J Clin Endocrinol Metab | Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. | 2013 | Details |
| A24042 | 23287807 | J Pediatr Gastroenterol Nutr | Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. | 2013 | Details |
| A24045 | 23285761 | Klin Med (Mosk) | [The prevalence of liver and gallbladder pathologies in overweight and obese patients]. | 2012 | Details |
| A24049 | 23280158 | Dig Liver Dis | Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. | 2012 | Details |
| A24062 | 24933975 | Eksp Klin Gastroenterol | [Efficiency of ursodeoxycholic acid therapy in non-alcoholic fatty liver disease associated with metabolic syndrome]. | 2013 | Details |
| A24113 | 23218652 | Gastroenterol Hepatol | [Acute liver failure after bariatric surgery. A case report and literature review]. | 2012 | Details |
| A24127 | 23203768 | Mol Nutr Food Res | Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways. | 2012 | Details |
| A24132 | 23197411 | Gut | Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. | 2012 | Details |
| A24157 | 23174203 | Proc Nutr Soc | The gut microbial metabolome: modulation of cancer risk in obese individuals. | 2012 | Details |
| A24197 | 23129794 | J Physiol | The role of fructose transporters in diseases linked to excessive fructose intake. | 2012 | Details |
| A24212 | 23113697 | Fundam Clin Pharmacol | Pharmacokinetics of cysteamine bitartrate following intraduodenal delivery. | 2012 | Details |
| A24275 | 23057494 | Aliment Pharmacol Ther | Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. | 2012 | Details |
| A24276 | 23055155 | Hepatology | Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. | 2013 | Details |
| A24426 | 22908056 | Hormones (Athens) | The pluses and minuses of bariatric surgery for morbid obesity: An endocrinological perspective. | 2013 | Details |
| A24496 | 22840293 | Gastrointest Endosc | Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. | 2012 | Details |
| A24511 | 22824479 | Clin Liver Dis | A myriad of pathways to NASH. | 2012 | Details |
| A24512 | 22824478 | Clin Liver Dis | Mechanisms of simple hepatic steatosis: not so simple after all. | 2012 | Details |
| A24561 | 22749137 | J Nutr Biochem | Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. | 2012 | Details |
| A24570 | 22740094 | Endocrine | A pathogenetic link between non-alcoholic fatty liver disease and celiac disease. | 2012 | Details |
| A24600 | 22706738 | Turk J Gastroenterol | Effects of probiotics on methionine choline deficient diet-induced steatohepatitis in rats. | 2012 | Details |
| A24605 | 22700625 | Ann Hepatol |  Gut microbiota and nonalcoholic fatty liver disease. | 2012 | Details |
| A24624 | 22678663 | Cell Mol Life Sci | Studying non-alcoholic fatty liver disease with zebrafish: a confluence of optics, genetics, and physiology. | 2012 | Details |
| A24639 | 22661622 | J Am Coll Nutr | Probiotics in the treatment of the liver diseases. | 2012 | Details |
| A24650 | 22648540 | Histol Histopathol | Farnesoid X Receptor (FXR) from normal to malignant state. | 2012 | Details |
| A24661 | 22643316 | Clin Chim Acta | IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. | 2012 | Details |
| A24708 | 22576368 | Mol Med | Apolipoprotein A-I modulates processes associated with diet-induced nonalcoholic fatty liver disease in mice. | 2012 | Details |
| A24714 | 22569763 | J Gastroenterol | Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. | 2012 | Details |
| A24739 | 22546554 | Nutr Metab Cardiovasc Dis | Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. | 2012 | Details |
| A24745 | 22543623 | Eur J Nutr | A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): a pilot study. | 2012 | Details |
| A24764 | 22525431 | Lab Invest | Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. | 2012 | Details |
| A24808 | 22469640 | J Clin Gastroenterol | The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. | 2012 | Details |
| A24858 | 22427130 | Dig Dis Sci | Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). | 2012 | Details |
| A24913 | 22367065 | Dig Dis Sci | Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis. | 2012 | Details |
| A24938 | 22340564 | Chin Med J (Engl) | Intestinal immune barrier integrity in rats with nonalcoholic hepatic steatosis and steatohepatitis. | 2012 | Details |
| A24966 | 22300605 | Endocrinol Nutr | The role of gut hormones in controlling the food intake: what is their role in emerging diseases? | 2012 | Details |
| A25013 | 22247604 | J Clin Biochem Nutr | Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. | 2011 | Details |
| A25040 | 22221818 | Liver Int | The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. | 2011 | Details |
| A25058 | 24829632 | Middle East J Dig Dis | Common Digestive and Liver Diseases among 5880 Patients Admitted to Shariati Hospital,Tehran,Iran during 2000-2009. | 2012 | Details |
| A25152 | 22132342 | J Lipids | Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. | 2011 | Details |
| A25173 | 22112382 | Drug Metab Dispos | Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. | 2011 | Details |
| A25190 | 22105182 | J Clin Gastroenterol | Coronary artery stents and antiplatelet therapy in patients with cirrhosis. | 2012 | Details |
| A25206 | 22094893 | Curr Top Microbiol Immunol | Contribution of the intestinal microbiota to human health: from birth to 100 years of age. | 2013 | Details |
| A25240 | 22059109 | World J Hepatol | Role of ezetimibe in non-alcoholic fatty liver disease. | 2011 | Details |
| A25273 | 22018861 | Br J Nutr | Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. | 2011 | Details |
| A25278 | 22013810 | Zhongguo Zhong Xi Yi Jie He Za Zhi | [The key target of Chinese medicine treatment on alcoholic and nonalcoholic fatty liver disease: the gut]. | 2011 | Details |
| A25384 | 21903748 | J Pharmacol Exp Ther | Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice. | 2011 | Details |
| A25385 | 21901256 | Dig Dis Sci | Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. | 2011 | Details |
| A25453 | 21817060 | Am J Physiol Gastrointest Liver Physiol | Altered lipid metabolism in Hfe-knockout mice promotes severe NAFLD and early fibrosis. | 2011 | Details |
| A25464 | 21805421 | Turk J Gastroenterol | The prevalence of celiac disease among patients with non-alcoholic fatty liver disease in Iran. | 2011 | Details |
| A25533 | 21740407 | Br J Pharmacol | Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis. | 2012 | Details |
| A25570 | 21703208 | J Hepatol | DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. | 2011 | Details |
| A25597 | 21671974 | Scand J Immunol | Resistin is associated with breach of tolerance and anti-nuclear antibodies in patients with hepatobiliary inflammation. | 2011 | Details |
| A25670 | 21563361 | Eksp Klin Gastroenterol | [Advisability of using probiotics in the treatment of atherogenic dyslipidemia]. | 2011 | Details |
| A25764 | 21476914 | Expert Rev Gastroenterol Hepatol | Inflammation in nonalcoholic steatohepatitis. | 2011 | Details |
| A25842 | 21403438 | Gan To Kagaku Ryoho | [Helicobacter pylori infection and liver diseases]. | 2011 | Details |
| A25850 | 21395631 | Aliment Pharmacol Ther | Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. | 2011 | Details |
| A25939 | 21292470 | J Nutr Biochem | Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. | 2011 | Details |
| A25953 | 21274430 | Gastroenterol Res Pract | Role of toll-like receptors and their downstream molecules in the development of nonalcoholic Fatty liver disease. | 2011 | Details |
| A26040 | 21178608 | Curr Opin Clin Nutr Metab Care | Nonalcoholic fatty liver disease in children. | 2011 | Details |
| A26084 | 21129376 | Gastroenterology | Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. | 2010 | Details |
| A26097 | 21109326 | J Hepatol | Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas. | 2010 | Details |
| A26131 | 21045794 | Nat Rev Gastroenterol Hepatol | The role of the gut microbiota in nonalcoholic fatty liver disease. | 2010 | Details |
| A26132 | 21044019 | Curr Vasc Pharmacol | Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. | 2011 | Details |
| A26152 | 21033080 | Eksp Klin Gastroenterol | [Hypolipidemic therapy in patients with non-alcoholic fatty liver disease]. | 2010 | Details |
| A26164 | 20970047 | Crit Care Clin | Gastrointestinal system and obesity. | 2010 | Details |
| A26179 | 20947198 | J Hepatol | Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. | 2010 | Details |
| A26188 | 20939104 | World J Gastroenterol | Fat: a matter of disturbance for the immune system. | 2010 | Details |
| A26213 | 20880342 | Diabetes Obes Metab | Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events. | 2010 | Details |
| A26226 | 20868235 | Biol Chem | Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice. | 2010 | Details |
| A26240 | 20847296 | J Lipid Res | Protective effect of bile acids on the onset of fructose-induced hepatic steatosis in mice. | 2010 | Details |
| A26247 | 20842181 | Nat Rev Endocrinol | Morbid obesity in pediatric diabetes mellitus: surgical options and outcomes. | 2010 | Details |
| A26272 | 20804522 | Obes Rev | Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? | 2010 | Details |
| A26292 | 20716048 | Exp Clin Transplant | Acute gastric variceal bleeding during orthotopic liver transplant. | 2010 | Details |
| A26356 | 20601094 | Drug Discov Today | Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? | 2010 | Details |
| A26364 | 20584230 | Int J Clin Pract | Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. | 2010 | Details |
| A26405 | 22444262 | Animal | Porcine models for the metabolic syndrome, digestive and bone disorders: a general overview. | 2010 | Details |
| A26475 | 20421811 | J Clin Gastroenterol | Serum B12 concentration is elevated in patients receiving chronic parenteral nutrition, but is not a marker of intestinal failure-associated liver disease. | 2010 | Details |
| A26527 | 20361370 | Chirurg | [Indications and principles of metabolic surgery]. | 2010 | Details |
| A26548 | 20226139 | Zhong Xi Yi Jie He Xue Bao | [Pathogenesis and treatment of non-alcoholic fatty liver disease]. | 2010 | Details |
| A26552 | 20221393 | PLoS One | Role of alcohol metabolism in non-alcoholic steatohepatitis. | 2010 | Details |
| A26612 | 20093562 | Am J Physiol Gastrointest Liver Physiol | The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. | 2010 | Details |
| A26631 | 20059344 | Annu Rev Med | Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. | 2010 | Details |
| A26647 | 21525758 | Dig Dis | Gut-liver axis and sensing microbes. | 2011 | Details |